In order for our site to display correctly you will need a newer version of your web browser.
The following browsers support numerous web standards including CSS,XHTML, and the DOM (a universal means of controlling the behavior of web pages):
- Netscape v7 or higher (all platforms), Mozilla FireFox (Windows), Camino (Mac OS X), Galeon (Linux GNOME Desktop) or other browser stemming from the Mozilla.org project.
- Opera v7 or higher (Windows, Linux)
- Apple's Safari (Mac OS X)
- Konqueror (Linux KDE Desktop)
- Microsoft Internet Explorer v6 or higher (Windows) or v5 or higher (Macintosh)
Please note that this is not intended be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Finding Cures. Saving Children.
Charles J. Sherr, MD, PhD
Member, St. Jude Faculty
Co-Chair, Genetics & Tumor Cell Biology
Investigator, Howard Hughes Medical Institute
Co-Director, Molecular Oncology Program
Herrick Foundation Chair
Departments
Genetics / Tumor Cell Biology
Contact Information
Charles Sherr, MD, PhD
Genetics / Tumor Cell Biology
MS 350, Room D-5006D
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Education
MD - New York University School of Medicine
PhD - New York University Graduate School of Arts and Sciences
Research Interests
Our laboratory has traditionally focused on the mechanisms by which mitogens relay proliferative signals that affect progression through the mammalian cell division cycle. Current projects emphasize the rate limiting effects of cyclins and cyclin-dependent kinases (CDKs) on G1 phase progression; the role of CDK inhibitors (INK4 and Cip/Kip proteins) in cell cycle control, organismal development, and tumorigenesis in vivo; the activity of particular tumor suppressors, including INK4A-ARF, p53, and RB, in cell line establishment, senescence, stem cell biology, and protecting against oncogenic insults. Postdoctoral fellows and graduate students receive joint supervision by Drs. Roussel and Sherr in a multi-disciplinary program that seeks to maximize trainees’ abilities to successfully perform novel and speculative experiments.
Selected Publications
Gromley A, Churchman ML, Zindy F, Sherr CJ. Transient expression of the Arf tumor suppressor during male germ cell and eye development in Arf-Cre reporter mice. Proc Natl Acad Sci USA 106: 6285-6290, 2009.
Williams RT and Sherr CJ. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias. Cold Spring Harbor Symp Quant Biol 73:461-467, 2008.
Kuo M-L, den Besten W, Thomas MC, Sherr CJ. Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 protease Senp3. Cell Cycle 7: 3378-3387, 2008.
Williams RT, den Besten W, Sherr CJ. Cytokine-dependent imatinib resistance in mouse BCR-ABL(+), Arf-null lymphoblastic leukemia. Genes Dev 21: 2283-2287, 2007.
Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6: 663-673, 2006.
Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci USA 103: 6688-6693, 2006.
Sherr CJ. Review: Principles of Tumor Suppression. Cell (30th Anniversary Issue) 116: 235-246, 2004.
Last update: June 2009
